Literature DB >> 11551095

Psychosocial impact of C282Y mutation testing for hemochromatosis.

T E Power1, P C Adams.   

Abstract

The aim of this study was to investigate the psychological effects of genetic testing for hemochromatosis. Study participants included cases discovered through a population screening study in 5211 voluntary blood donors (n = 25) and patients referred for diagnostic evaluation for hemochromatosis (n = 117). Participants completed questionnaires (Spielberger State-Trait Anxiety Index, Medical Outcomes Survey Short Form 36) before and after genetic testing. A subset of participants from the screening study was also interviewed 1 year after testing (Feelings About Test Results Measure). Additional questions included data on insurance applications, time off from work, and family issues. Anxiety significantly decreased in homozygotes and heterozygotes after genetic testing and remained constant in C282Y mutation-negative cases. Vitality and physical composite scores improved after genetic testing. There were no significant deleterious psychological effects of genetic testing on anxiety and on mental and physical health status. There were no negative effects discovered on insurance or time off work. This study has not demonstrated deleterious effects of genetic testing for hemochromatosis on anxiety, mental health and physical health status, insurance, or time off from work. Genetic testing for hemochromatosis is well accepted and should not be discouraged on the basis of potential adverse psychosocial effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551095     DOI: 10.1089/109065701753145556

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  9 in total

1.  The diagnosis and management of hereditary haemochromatosis.

Authors:  Paul Clark; Laurence J Britton; Lawrie W Powell
Journal:  Clin Biochem Rev       Date:  2010-02

Review 2.  A diagnostic approach to hemochromatosis.

Authors:  Anthony S Tavill; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

3.  Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?

Authors:  E Cadet; D Capron; M Gallet; M-L Omanga-Léké; H Boutignon; C Julier; K J H Robson; J Rochette
Journal:  J Med Genet       Date:  2005-05       Impact factor: 6.318

4.  ironXS: high-school screening for hereditary haemochromatosis is acceptable and feasible.

Authors:  Martin B Delatycki; Michelle Wolthuizen; Veronica Collins; Elizabeth Varley; Joanna Craven; Katrina J Allen; Lyle C Gurrin; Maryanne Aitken; M Kaye Trembath; Lyndal Bond; Gabrielle R Wilson; Sarah E M Stephenson; Ivan Macciocca; Chriselle Hickerton; Paul J Lockhart; Sylvia A Metcalfe
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

5.  Psychological adjustment and knowledge about hereditary hemochromatosis in a clinic-based sample: a prospective study.

Authors:  Bettina Meiser; Stewart Dunn; Jeannette Dixon; Lawrie W Powell
Journal:  J Genet Couns       Date:  2005-12       Impact factor: 2.537

Review 6.  The myths and realities of hemochromatosis.

Authors:  Melanie D Beaton; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2007-02       Impact factor: 3.522

Review 7.  Hemochromatosis. Common genes, uncommon illness?

Authors:  Helen Harrison; Paul C Adams
Journal:  Can Fam Physician       Date:  2002-08       Impact factor: 3.275

8.  Biological variability of transferrin saturation and unsaturated iron-binding capacity.

Authors:  Paul C Adams; David M Reboussin; Richard D Press; James C Barton; Ronald T Acton; Godfrey C Moses; Catherine Leiendecker-Foster; Gordon D McLaren; Fitzroy W Dawkins; Victor R Gordeuk; Laura Lovato; John H Eckfeldt
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

9.  Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.

Authors:  Michael R Cassidy; J Scott Roberts; Thomas D Bird; Ellen J Steinbart; L Adrienne Cupples; Clara A Chen; Erin Linnenbringer; Robert C Green
Journal:  Alzheimers Dement       Date:  2008-11       Impact factor: 21.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.